Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type

American Journal of Pathology

Volumn 187, Issue 5, 2017, Pages 980-986

  Sim, Sung Hoon ^a,b   Kim, Soyeon ^b   Kim, Tae Min ^a,b   Jeon, Yoon Kyung ^a,b   Nam, Soo Jeong ^a,b   Ahn, Yong Oon ^b   Keam, Bhumsuk ^a,b   Park, Hyun Ho ^c   Kim, Dong Wan ^a,b   Kim, Chul Woo ^a,b   Heo, Dae Seog ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Yeungnam University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GENOMIC DNA; IFOSFAMIDE; INTERLEUKIN 3; JANUS KINASE 3; METHOTREXATE; PREDNISOLONE; PROTEIN INHIBITOR; STAT3 PROTEIN; STATTIC; TOFACITINIB; UNCLASSIFIED DRUG; VINCRISTINE; JAK3 PROTEIN, HUMAN; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFOXIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; DIFFUSE LARGE B-CELL LYMPHOMA CELL LINE; DIRECT SEQUENCING; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATION RATE; MUTATIONAL ANALYSIS; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PSEUDOKINASE DOMAIN; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; T-CELL LYMPHOMA CELL LINE; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; MUTATION; NOSE TUMOR; PHOSPHORYLATION; TUMOR CELL CULTURE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CYCLIC S-OXIDES; FEMALE; HUMANS; JANUS KINASE 3; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; MUTATION; NOSE NEOPLASMS; PHOSPHORYLATION; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 85019045647     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2017.01.004     Document Type: Article

References (20)

1. 1 Chan, J.K., Jaffe, E.S., Ralfkiaer, E., Extranodal NK/T-cell lymphoma, nasal type. Jaffe, E.S., Harris, N.L., Stein, H., Vardiman, J.W., (eds.) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2001, IARC, Lyon, France, 204–207.
2. 2 Chan, J.K., Quintanilla-Martinez, L., Ferry, J.A., Peh, S.C., Extranodal NK/T-cell lymphoma, nasal type. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., Vardiman, J.W., (eds.) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2008, IARC, Lyon, France, 285–288.
3. 3 Kim, M., Kim, T.M., Kim, K.H., Keam, B., Lee, S.H., Kim, D.W., Lee, J.S., Jeon, Y.K., Kim, C.W., Heo, D.S., Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL). Ann Hematol 94 (2015), 437–444.
4. 4 Coppo, P., Gouilleux-Gruart, V., Huang, Y., Bouhlal, H., Bouamar, H., Bouchet, S., Perrot, C., Vieillard, V., Dartigues, P., Gaulard, P., Agbalika, F., Douay, L., Lassoued, K., Gorin, N.C., STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma. Leukemia 23 (2009), 1667–1678.
5. 5 Koo, G.C., Tan, S.Y., Tang, T., Poon, S.L., Allen, G.E., Tan, L., Chong, S.C., Ong, W.S., Tay, K., Tao, M., Quek, R., Loong, S., Yeoh, K.W., Yap, S.P., Lee, K.A., Lim, L.C., Tan, D., Goh, C., Cutcutache, I., Yu, W., Ng, C.C., Rajasegaran, V., Heng, H.L., Gan, A., Ong, C.K., Rozen, S., Tan, P., Teh, B.T., Lim, S.T., Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov 2 (2012), 591–597.
6. 6 Kucuk, C., Jiang, B., Hu, X., Zhang, W., Chan, J.K., Xiao, W., Lack, N., Alkan, C., Williams, J.C., Avery, K.N., Kavak, P., Scuto, A., Sen, E., Gaulard, P., Staudt, L., Iqbal, J., Zhang, W., Cornish, A., Gong, Q., Yang, Q., Sun, H., d'Amore, F., Leppa, S., Liu, W., Fu, K., de Leval, L., McKeithan, T., Chan, W.C., Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat Commun, 6, 2015, 6025.
7. 7 Jiang, L., Gu, Z.H., Yan, Z.X., Zhao, X., Xie, Y.Y., Zhang, Z.G., et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat Genet 47 (2015), 1061–1066.
8. 8 Lee, S., Park, H.Y., Kang, S.Y., Kim, S.J., Hwang, J., Lee, S., Kwak, S.H., Park, K.S., Yoo, H.Y., Kim, W.S., Kim, J.I., Ko, Y.H., Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. Oncotarget 6 (2015), 17764–17776.
9. 9 Bouchekioua, A., Scourzic, L., de Wever, O., Zhang, Y., Cervera, P., Aline-Fardin, A., Mercher, T., Gaulard, P., Nyga, R., Jeziorowska, D., Douay, L., Vainchenker, W., Louache, F., Gespach, C., Solary, E., Coppo, P., JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia 28 (2014), 338–348.
10. 10 Kimura, H., Karube, K., Ito, Y., Hirano, K., Suzuki, M., Iwata, S., Seto, M., Rare occurrence of JAK3 mutations in natural killer cell neoplasms in Japan. Leuk Lymphoma 55 (2014), 962–963.
11. 11 Biasini, M., Bienert, S., Waterhouse, A., Arnold, K., Studer, G., Schmidt, T., Kiefer, F., Gallo Cassarino, T., Bertoni, M., Bordoli, L., Schwede, T., SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 42 (2014), W252–W258.
12. 12 Lupardus, P.J., Ultsch, M., Wallweber, H., Bir Kohli, P., Johnson, A.R., Eigenbrot, C., Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc Natl Acad Sci U S A 111 (2014), 8025–8030.
13. 13 Yan, J., Li, B., Lin, B., Lee, P.T., Chung, T.H., Tan, J., Bi, C., Lee, X.T., Selvarajan, V., Ng, S.B., Yang, H., Yu, Q., Chng, W.J., EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma. Blood 128 (2016), 948–958.
14. 14 Miao, D., Zhang, L., Leptin modulates the expression of catabolic genes in rat nucleus pulposus cells through the mitogen-activated protein kinase and Janus kinase 2/signal transducer and activator of transcription 3 pathways. Mol Med Rep 12 (2015), 1761–1768.
15. 15 Lee, E.B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J.D., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G.V., Zang, C., Zwillich, S.H., van Vollenhoven, R.F., Investigators, O.S., Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370 (2014), 2377–2386.
16. 16 Hanna, D.M., Fellowes, A., Vedururu, R., Mechinaud, F., Hansford, J.R., A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy. Haematologica 99 (2014), e156–e158.
17. 17 Bilori, B., Thota, S., Clemente, M.J., Patel, B., Jerez, A., Afable Ii, M., Maciejewski, J.P., Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia. Leukemia 29 (2015), 2427–2429.
18. 18 O'Shea, J.J., Holland, S.M., Staudt, L.M., JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368 (2013), 161–170.
19. 19 Koskela, H.L., Eldfors, S., Ellonen, P., van Adrichem, A.J., Kuusanmaki, H., Andersson, E.I., Lagstrom, S., Clemente, M.J., Olson, T., Jalkanen, S.E., Majumder, M.M., Almusa, H., Edgren, H., Lepisto, M., Mattila, P., Guinta, K., Koistinen, P., Kuittinen, T., Penttinen, K., Parsons, A., Knowles, J., Saarela, J., Wennerberg, K., Kallioniemi, O., Porkka, K., Loughran, T.P. Jr., Heckman, C.A., Maciejewski, J.P., Mustjoki, S., Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 366 (2012), 1905–1913.
20. 20 Huang, X., Meng, B., Iqbal, J., Ding, B.B., Perry, A.M., Cao, W., Smith, L.M., Bi, C., Jiang, C., Greiner, T.C., Weisenburger, D.D., Rimsza, L., Rosenwald, A., Ott, G., Delabie, J., Campo, E., Braziel, R.M., Gascoyne, R.D., Cook, J.R., Tubbs, R.R., Jaffe, E.S., Armitage, J.O., Vose, J.M., Staudt, L.M., McKeithan, T.W., Chan, W.C., Ye, B.H., Fu, K., Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 31 (2013), 4520–4528.